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Abstract: A complication of diabetes is diabetic ketoacidosis (DKA), which if left untreated is a life
threatening condition. Prompt and accurate diagnosis of DKA is required for the commencement
of life saving interventions. Measurements of ketone bodies in DKA have usually been through
nitroprusside urine acetoacetate testing. The aim of this systematic review was to examine whether
capillary β-hydroxybutyrate (β-OHB) testing is more accurate compared to other diagnostic methods
of DKA. The following electronic databases were searched: EBSCO Host, MEDLINE, PSYCHInfo,
CINAHL and Science Direct for publications from 1 January 2005 and up to and including 1 January
2016. Inclusion criteria were: Adults 18 years and over and known type 1 or type 2 diabetes.
Retrospective and prospective observation studies were included. A total of nine studies met the
inclusion criteria. Capillary β-OHB was found to have high sensitivity, specificity, positive predictive
value and negative predictive value in identifying DKA compared to urinary ketone testing.
Keywords: diabetes ketoacidosis; type 1 diabetes; type 2 diabetes; emergency department; point of
care testing; ketones
1. Introduction
Diabetic Ketoacidosis (DKA) is a life threatening complication of diabetes, which is characterized
by a triad of hyperglycaemia, ketosis and metabolic acidosis [1–3]. It results from absolute or
relative insulin deficiency leading to the failure of glucose to enter the cells for the normal metabolic
pathways. Therefore, the lack of insulin secretion triggers the release of counter regulatory hormones
including cathecholamines, glucagon and cortisol. The imbalance in hormone leads to hepatic
gluconeogenesis and glycogenolysis, resulting in severe hyperyglycemia [1]. Although lipolysis
is a normal biochemical process, it becomes unregulated in DKA. The process of ketone production
in DKA involves the formation of serum free fatty acids, which are used for the production of large
quantities of ketone bodies (acetoacetate, β-hydroxybutyrate (β-OHB), and acetone), and consequent
metabolic acidosis [1,3]. While the liver is the site of ketone formation, the first ketone body produced
is acetoacetic acid, which is reduced to β-OHB or acetone [2]. Therefore, the β-OHB to acetoacetate
ratio, which is 1:1 in its normal state, is usually elevated to at least 3:1 in diabetic ketoacidosis at
presentation [4] and may be as much as 10:1 [5]. β-OHB levels are the most abundant in the blood in
DKA, representing 75% of total ketones formed [6]. The blood β-OHB levels below 0.6 mmol/L are
Int. J. Environ. Res. Public Health 2016, 13, 837; doi:10.3390/ijerph13090837 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2016, 13, 837 2 of 9
regarded as normal, while levels over 1 mmol/L represent hyperketonemia, and levels in excess of
3 mmol/L indicate ketoacidosis [6].
The characteristic features of DKA, such as osmotic diuresis resulting from hyperglycaemia, may
lead to fluid depletion, dehydration and electrolyte imbalance [1]. According to Klocker et al. [7]
and Mackay et al. [8], DKA may occur during episodes of infection, stress, insulin omission and
interruption of insulin by an insulin pump.
Although DKA is most common in patients with Type 1 diabetes, it may also occur in those
with Type 2 diabetes. It accounts for 8%–29% of all hospital admissions of patients with diabetes as
the primary diagnosis with average mortality rates of 5%–10%, and as high as 15% in the elderly
population [9]. It should be emphasised that patients require prompt recognition, treatment and
monitoring from health care professional.
In patients with DKA, it is essential to take the patient’s history and review the presenting
signs and symptoms which may include excessive thirst, feeling tired and lethargic, blurred vision,
abdominal pain, nausea, vomiting, and changes in respiration [10]. In addition, physical examination
should be conducted and blood and urine tests should be carried out in order to provide preliminary
diagnosis of DKA [11]. The measurement of ketone bodies in either serum or urine is often
undertaken by dipsticks, which rely on the nitroprusside test that changes the colour of the stick
to purple–violet [12]. According to Dhatariya the urine ketone stick test such as Ketostix by Bayer
Diabetes, Berkshire, UK, gives a semi-quantitative measurement of acetoacetate and not β-OHB
which is the most predominant ketone body in DKA [13]. In addition, there are other limitations
with the use of the dipsticks for carrying out these tests. For example, the use of urinary dipstick
ketone test in DKA diagnosis and management may be unreliable because β-OHB is converted to
acetoacetate during treatment of DKA [4]. In addition, urine sample can take time or may even
be impossible in seriously ill patients in the emergency setting [14,15]. On the other hand, Misra
and Oliver, and Katsilambros et al. noted that measurement of ketones from samples of serum,
plasma, or whole blood may involve using laboratory based analysers or from finger prick samples
using capillary blood [12,16]. These samples can be analysed for β-OHB using different assays,
such as spectrophotometry, colorimetric, gas chromatography, capillary electrophoresis and enzymatic,
although the enzymatic method appear to be the most widely used [16]. The enzymatic method for
β-OHB measurement described by Noyes et al. [5] involved the use of Hitachi 911 analyser (Roche
Diagnostic, London, UK) in which β-OHB dehydrogenase catalyses the conversion of the D isomer
of β-OHB and nicotine amide dinucleotide (NAD) to acetoacetate and nicotine amide dinucleotide
hydrogen (NADH) at pH 8.5.
However, laboratory measurement of β-OHB is not routinely available and it takes too long to be
of practical use in the emergency diagnosis and in the management of DKA in home settings [17,18].
Therefore, the use of new meters, which can measure β-OHB in capillary blood, are now available
although the accuracy of these new meters have not been well tested against other methods. In the
UK, two meters used to measure capillary blood ketone concentrations are the GlucoMen LX Plus
by Menarini Diagnostics and Freestyle Optium Neo by Abbot Diabetes care [13]. In contrast to the
laboratory methods of detecting β-OHB [5] reported in their study that a 5-µL finger prick capillary
blood sample is required for the measurement of capillary β-OHB and results are usually displayed
within 30 s. The meter analytical range was 0–6 mmol/L, with results >6 mmol/L being displayed
as “HI”. The American Diabetes Association, since 2004 [19], has recommended blood β-OHB for
diagnosis and treatment of ketoacidosis.
In a previous systematic review which examined the use of blood β-OHB and urine acetoacetate
testing for the prevention of and management of ketoacidosis, Klocker et al. [7] focused only on
patients with Type 1 diabetes and with age of subjects below 22 years. However, the focus of the
current review was adults over the age of 18 with Type 1 or Type 2 diabetes.
Based on the above, the aim of this review is to evaluate whether capillary β-OHB measurement
is more accurate compared to other measurements in the diagnosis and management in patients
presenting with diabetic ketoacidosis.
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The objective is as follows:
• To examine the use of capillary β-OHB compared to urinary and laboratory methods used in the
detection and management of diabetic ketoacidosis.
The research question is:
• Is capillary β-OHB as accurate in measuring ketones compared with urinary and laboratory
methods in patients with diabetic ketoacidosis?
2. Methods
The literature search strategy for this review relied on previously published guidelines for
systematic reviews [20,21]. A number of databases including EBSCO host, encompassing Academic
search premier, Medline, Psychology and Behavioural sciences collection, PSYCINFO, SPORTDISCUSS
and Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus and Science Direct
were accessed for relevant evidence. References of articles were also checked in order to find useful
evidence for the review. A range of search terms were used and these included medical subject
headings (MeSH), such as “diabetic ketoacidosis” (refer to Table 1).
Table 1. Literature search strategy.
Key Words Search Engine Hits Search Engine Hits
Diabetic ketoacidosis EBSCO host * 5583 Science Direct 2299
“Diabetic ketoacidosis“ and “beta hydroxybutyrate“ EBSCO host 109 Science Direct 159
“Diabetic ketoacidosis“and “acetoacetate“ EBSCO host 43 Science Direct 113
Early detection of ketones EBSCO host 3 Science Direct 12
“Diabetic ketoacidosis“ and “point of care testing“ EBSCO host 38 Science Direct 663
“Diabetic ketoacidosis“ and “early detection of ketones“ EBSCO host 1 Science Direct 83
“Diabetic ketoacidosis“ and “measurement of blood ketones“ EBSCO host 12 Science Direct 185
“Diabetic ketoacidosis“ and “enzymatic method“ EBSCO host 9 Science Direct 171
“Diabetic ketoacidosis“ and “blood ketones“ EBSCO host 85 Science Direct 1636
“Diabetic ketoacidosis“ and “urine ketones“ EBSCO host 81 Science Direct 1096
“Diabetic ketoacidosis“ and “capillary ketones“ EBSCO host 10 Science Direct 433
“Diabetic ketoacidosis“ and “serum beta hydroxybutyrate“ EBSCO host 8 Science Direct 401
“Diabetic ketoacidosis“ and “laboratory analysis“ EBSCO host 9 Science Direct 2059
* EBSCO host included: Academic Search Premier, Medline, Psychology and Behavioural Sciences Collection,
PSYCHOINFO, SPORTDISCUSS, and CINAHL.
In addition, “Bolean” operators allowing the combination of search terms such as “diabetic
ketoacidosis” and “blood ketones”; “diabetic ketoacidosis” and “capillary ketones”; “diabetic
ketoacidosis” and “capillary β-hydroxybutyrate”; “diabetic ketoacidosis” and “ketone, urine”
were used.
This review involved splitting the research question into its component parts, namely;
Population (P), Intervention (I), Comparative interventions (C) and Outcomes (O) based on the
PICO framework [20]. In this regard, the population of interest was patients with diabetes presenting
with diabetic ketoacidosis, while the intervention was the capillary blood ketone measurement and
the comparative interventions included urinary ketone testing. The outcomes of interests were the
ketone measurements obtained from these procedures and the accuracy in predicting a diagnosis of
diabetic ketoacidosis.
Int. J. Environ. Res. Public Health 2016, 13, 837 4 of 9
3. Inclusion Criteria
The selection of articles for this review was based on a number of set criteria. Firstly, the articles
selected were only those published between 2005 and 2016. This was to enable enough period of time
to have sufficient articles for the review.
Primary research articles based on original and/or new data were selected. In addition, studies
involving secondary data analysis based on retrospective and prospective studies were also included.
Articles selected were those written in English and included studies with participants aged 18 years
or over.
4. Exclusion Criteria
Studies involving children and animals were excluded from the review. In addition, duplicate
citations were identified and excluded. All studies that did not meet the criteria for inclusion were
excluded from the review.
5. Quality Assurance
In order to ensure the quality of this review, three researchers were independently involved in
the searches based on an agreed search criteria including search terms. Results of the searches were
then harmonised and evaluated. The evaluation process involved assessing the quality of the research
articles and this was based on previously published reviews, based on the experience of the researchers
and on the Scottish Intercollegiate Guidelines Network (SIGN) checklist for critical appraisal [7,22].
6. Results
The search identified nine studies that met the inclusion criteria of which: one compared capillary
β-OHB with blood glucose levels ≥10.0 mmols/L [4]; two compared capillary β-OHB with standard
measures (arterial blood gases, anion gap and carbon dioxide) of DKA [23,24], although one did not
include urine ketones [23]; one compared capillary β-OHB with the manual enzymatic method [25];
five compared capillary β-OHB with urine ketones in detecting DKA [6,14,25–27] (refer to Table 2).
The studies included a total of 2019 participants, with a range of 19–529. Studies were completed
in Australia [9], Banglaesh [27], France [14], Greece [25], Singapore [24], South Africa [28], Thailand [6],
and USA [23,26].
Due to inconsistencies in methodologies, definitions and cut off levels of capillary β-OHB and
blood glucose, and biological measures reported across the studies, a meta-analysis of the data was
not possible.
Of the five studies that compared capillary β-OHB with urine ketones, capillary β-OHB was found
to be equally as sensitive as urine ketones for detecting DKA at the level of >1.5 mmol/L, however,
capillary β-OHB was more specific than urine ketones (78.6% versus 35.1%) in the ED [26], whilst in
a small sample of 19 participants capillary β-OHB at the level of >3.0 mmols/L had a lower sensitivity
than urine ketones (90% versus 95%) and equal specificity of 100% [6]. In a sample of 50 participants
capillary β-OHB had a higher sensitivity, specificity and positive predictive value than urine ketones
(99.87% versus 89.89%, 92.89% versus 52.78%, and 92.89% versus 41.87%) in detecting DKA in ED [25].
However, in a sample of 121 participants capillary β-OHB at the level of >3.0 mmols/L as the reference
method, sensitivity of urine ketones was reported at 32.6% and specificity at 93.7%, with a positive
predictive value of 73.68% and negative predictive value of 71.84% [27]. The relative risk of DKA of
capillary β-OHB ≥ 3.0 mmols/L was higher than the measurement of +++ urine ketones 74 (95% CI:
48–88) versus 31 (95% CI: 18–45), low values of capillary β-OHB and urine ketones demonstrated
a good correlation, but a poor correlation between high values was found [14].
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Table 2. Overview of included studies.
Author Year,
Country Aim
Participants Measurement Method and
Operationalisation of
β-hydroxybutyrate (β-OHB)
Levels and Hyperglycaemia
Results Conclusion
Age (Mean ± Standard
Deviation (SD)
Gender, Diabetic Status
Tantiwong et al.
2005 [6],
Thailand
Comparison of capillary β-OHB
measurements with urine ketone testing
in diagnosing DKA.
19 DKA
(45.6 ± 16.95 years) Capillary blood ketones meter
(MediSense Optium™)
β-OHB ≥ 3.0 mmol/L
diagnostic of DKA
Blood glucose ≥ 250 mg/dL
(13.9 mmol/L)
The β-OHB value of >3.0 mmol/L had a sensitivity of 90% and a specificity of 100%, whereas urine
ketones had a sensitivity of 95% and a specificity of 100% in diagnosing DKA.
β-OHB and urine ketones are
effective to confirm DKA in
uncomplicated cases.
42.1% type 1 diabetes
38.8% type 2 diabetes
19.1% unclassified type
of diabetes
Naunheim et al.
2006 [23], USA
Comparison of capillary β-OHB
measurements with standard measures
(arterial blood gases, anion gap and carbon
dioxide) for accuracy in predicting DKA
in the ED.
160 (41 ± 15 years)
Capillary blood ketones meter
(Precision Xtra, Abbott Laboraotries)
No pre-operationalisation of
β-OHB levels
Blood glucose ≥ 250 mg/dL
High correlation between β-OHB levels and anion gap (r = 0.66, p < 0.001), carbon dioxide (r = −0.69,
p < 0.001), and blood glucose (r = 0.31, p < 0.001). A β-OHB test can accurately
identify patients with DKA,
adding this at triage is likely to
decrease delays in recognition of
DKA in ED.
46.8% female
103 Non-DKA (38 years)
The β-OHB value of >1.5 mmol/L had a sensitivity of 98% (95% CI: 91–100), a specificity of 85%
(95% CI: 78–91), with a positive likelihood ratio of 6.7 (95% CI: 4.22–10.78), and negative likelihood
ratio of 0.021 (95% CI: 0.003–0.144) of DKA.
57 DKA (38 years)
Raised blood glucose
Charles et al.
2007 [24],
Singapore
Comparison of capillary
β-OHB measurements with clinical
diagnosis, venous bicarbonate levels and
urine ketone testing in assessing DKA.
111 (median 60 years)
Capillary blood ketones meter
(MediSense Optium™)
No pre-operationalisation of
β-OHB levels
Blood glucose ≥ 14.0 mmol/L
The β-OHB value of 1.5 mmol/L compared with other diagnostic methods of DKA had a sensitivity
of 100% (95% CI: 59.0–100), a specificity of 93.3% (95% CI: 86.6–97.2), a positive predictive value of
50% (95% CI: 23.0–77.0), and a negative predictive value of 100% (95% CI: 96.3–100). β-OHB testing is a simple tool
that can support early
identification of DKA.
45.5% female
4.5% type 1 diabetes
The β-OHB value of 3.5 mmol/L, compared with other diagnostic measures of DKA had
a sensitivity of 100% (95% CI: 59.0–100), a specificity of 100% (95% CI: 96.5–100), a positive predictive
value of 100% (95% CI: 59.0–100) and a negative predictive value of 100% (95% CI: 96.5–100).95.5% type 2 diabetes
Taboulet et al.
2007 [14], France
Comparison of capillary β-OHB
measurements with urine ketone testing in
hyperglycaemic patients in the ED.
529 (53 ± 17 years)
Capillary blood ketones meter
(Optium, Abbott Laboratories)
β-OHB ≥ 1.0 mmol/L
Blood glucose ≥ 250 mg/dL
(13.9 mmol/L)
Urine ketones scored as +, ++ and +++ corresponded to medium capillary β-OHB levels of
0.5 mmol/L (IQR: 0.1–0.9), 0.7 mmol/L (IQR: 0.2–1.8) and 3 mmol/L (IQR: 1.4–5.2) respectively.
β-OHB is more accurate than
urine ketones to confirm
ketoacidosis in the ED.
36% female
Raised blood glucose The β-OHB value of ≥ 3.0 mmol/L was associated with the relative risk of DKA or hospitalization
74 (95% CI: 44–88) and 2.9 (95% CI: 2.5–3) respectively than ketones scored as +++ ketones 31
(95% CI: 18–45) and 2 (95% CI: 1.7–2.1) respectively.
Confirmed evaluation of blood ketones beyond 2.9 mmol/L is associated with higher risk of DKA
than +++ urine ketones.
Voulgari and
Tentolouris
2010 [25], Greece
Comparison of serum with capillary β-OHB
and urine ketones in detecting DKA in ED.
400 Non-DKA
(58.5 ± 9.7 years) Capillaroy blood ketones
(Precision-Xtra device Abbott
Laboratories)
β-OHB > 1.0 mmol/L
Blood glucose >13.9 mmol/L
Capillary and serum β-OHB were highly significantly correlated (r = 0.99, p < 0.001).
Capillary β-OHB of >3.0 mmol/L
offers the best combination of
sensitivity and specificity for
diagnosis of DKA.
The capillary β-OHB value of >3.0 mmol/L had a sensitivity of 99.87% and specificity of 92.89%
with positive predictive value of 92.89% for the diagnosis of DKA. Urine ketones had a sensitivity of
89.89% and specificity of 52.73% with positive predictive value of 41.87% for the diagnosis of DKA.
48% female
50 DKA (60.2 ± 8.2 years)
48% female
Insulin-treated type 2
diabetes
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Table 2. Cont.
Author Year,
Country Aim
Participants Measurement Method and
Operationalisation of
β-hydroxybutyrate (β-OHB)
Levels and Hyperglycaemia
Results Conclusion
Age (Mean ± Standard
Deviation (SD)
Gender, Diabetic Status
Arora et al.
2011 [26], USA
Comparison of capillary β-OHB
measurement with urine ketone testing in
assessment of DKA in the ED.
462 Non-DKA (48, age
range 40–57 years)
Capillary blood ketones meter
(Precision Xtra, Abbott Laboraotries)
β-OHB ≤ 1.5 mmol/L insignificant
β-OHB > 1.5 mmol/L raised
Blood glucose ≥ 250 mg/dL
Urine dipstick sensitivity of 98.1% (95% CI: 90.1–100), a specificity of 35.1% (30.7–39.6), a positive
predictive value of 15% (11.5–19.2) and a negative predictive value of 99.4% (96.6–100) for DKA. β-OHB is more specific than
urine ketone testing, therefore
β-OHB testing could significantly
reduce unnecessary DKA
work-ups in the ED.
35.3% female
44.5% insulin-requiring
The β-OHB value of >1.5 mmol/L had a sensitivity of 98.1% (95% CI: 90.1–100), a specificity of 78.6%
(74.5–82.2), a positive predictive value of 34.9% (27.3–43) and a negative predictive value of 99.7%
(95% CI: 98.5–100) of DKA.
54 DKA (41, age range
30–48 years)
27.8% female
56.6% insulin requiring
Kinsella et al.
2012 [9],
Australia
The use of capillary β-OHB measurement in
early assessment of hyperglycaemia in the
Emergency Department (ED)
72 (60.97 ± 22.07 years) Capillary blood ketones meter (Optium
Xceed—Abbott Laboratories, Illinois)
β-OHB ≥ 1.0 mmol/L elevated
Blood glucose ≥ 10.0 mmol/L
Modest correlation between capillary β-OHB levels and blood glucose levels on presentation (r =
0.29, p = 0.02) and over the ED stay (r = 0.21, p = 0.01)
β-OHB testing can support early
identification of DKA in the ED.
56.9% female
Insulin-requiring
diabetics
Rashid et al.
2013 [27],
Bangladesh
Comparison of capillary β-OHB levels with
serum electrolytes, urea and creatinine,
plasma glucose, and urine ketone testing in
assessing and managing DKA.
121 (39 ± 15 years) Biosensor method (Medisense)
β-OHB ≥ 3.0 mmol/L diagnostic
of DKA
Blood glucose ≥ 12.0 mmol/L
The relative frequencies of DKA, using urinary ketone and capillary β-OHB were 15.6% and 13.9%.
Using capillary β-OHB as the reference method, the sensitivity of urinary ketones were 32.6% and
the specificity was 93.7%, the positive predictive value, and negative predictive value of urine
ketones against blood ketones were 73.68% and 71.84% respectively.
Urine ketone testing has severe
limitations in assessing for DKA
in patients with type 2 diabetes,
with an error of 25%–30%.
36% female
100% type 2 diabetes
Coetzee et al.
2015 [28],
South Africa
Comparison of capillary β-OHB
measurement and the gold-standard manual
enzymatic method in assessment of DKA
41 (33, age range
17–52 years)
Capillary blood ketones meter (Optium
Xceed, Medisense/Abbott)
β-OHB < 1.0 mmol/L insignificant
β-OHB ≥ 3.0 mmol/L diagnostic
of DKA
Blood glucose > 13.9 mmol/L
High correlation between capillary β-OHB levels and the manual enzymatic method (r = 0.95)
β-OHB capillary testing is as
accurate and precise as the
manual enzymatic method in
confirming DKA.
58.5% female Capillary β-OHB levels when compared to the manual enzymatic method demonstrated a
sensitivity of 100% and a specificity of 89.5% for diagnosing DKA and a sensitivity of 100% and a
specificity of 87.3% for excluding DKA.
70.7% type 1 diabetes
29.3% type 2 diabetes
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Of the two studies that compared capillary β-OHB with standard measures of DKA, capillary
β-OHB value of >1.5 mmols/L had a sensitivity 100% and 98%, specificity of 93.3% and 85%, positive
predictive value of 50%, and a negative predictive value of 100%, a positive likelihood ratio of
6.7 (95% CI: 4.22–10.78) and a negative likelihood ratio of 0.021 (95% CI: 0.003–0.144) of detecting
hyperketonaemia [23,24]. Whereas a capillary β-OHB value of >3.5 mmols/L had a sensitivity 100%,
specificity of 100%, positive predictive value 100%, and a negative predictive value of 100% [24] of
detecting DKA.
Two studies found a modest and high correlation between blood glucose and capillary β-OHB
(r = 29, p = 0.02 and r = 0.3, p < 0.001) [9,23].
7. Discussion
Based on the results of this review there is evidence of differences in terms of sensitivity, specificity,
positive predictive value and negative predictive value between capillary β-OHB testing and urinary
ketone testing. The differences observed could be due to a number of factors. Firstly, urinary ketone
test involves a reaction between nitroprusside and acetoacetate which leads to a colour change on the
test strip that is then compared subjectively against a reference standard [8]. This procedure is time
dependent and it is therefore advised to disregard the colour changes after two minutes. Furthermore,
the nitroprusside test does not detect β-OHB, while sulphydryl drugs, such as captopril could cause
false–positive results and exposure of the test strips to air may lead to false–negative outcomes [8].
In contrast, the meter method for testing capillary blood ketone measures mainly β-OHB, which
is the predominant ketone in DKA and usually oxidised to acetoacetate as the ketosis resolves [5,13].
According to Yu et al. [29], due to the fact that β-OHB is metabolised to acetoacetate during treatment,
the ketone levels in urine often rise despite decreasing concentration of blood β-OHB. Therefore,
the urine ketone testing may give misleading information about the degree of ketosis and/or may
suggest that the DKA is not resolving [5]. Dhatariya [13] argued that urine ketone test measures the
average concentration in the urine that is held in the bladder since the last elimination and this may
have implications for patients with DKA who are often dehydrated.
The high correlation between capillary β-OHB levels and the manual enzymatic method is in
line with previous report, which showed good correlation between these meters and enzymatic
spectrophotometric assays [16].
It was also clear from this review that β-OHB compared well with other measures of DKA such as
carbon dioxide and blood glucose and is in tandem with previous reports. According Klocker et al. [7],
β-OHB is the predominant ketone body in DKA and correlates well with acidosis. In addition, Federici
and Benedetti [18] observed that different authors have indicated that capillary β-OHB levels showed
a relationship with the level of metabolic control as defined by glucose and HBA1c. For example,
it has been demonstrated that capillary β-OHB levels are closely related with other markers of DKA
including free fatty acid levels and blood pH [18].
The importance of capillary β-OHB testing was highlighted for a number of reasons; in one study
over half of participants were not able to produce a urine sample in ED [24], one study identified
three cases of DKA mortality where a negative test for urine ketones had been recorded, and urine
ketones did not demonstrate or correlate with the severity of capillary β-OHB, as low urine ketones in
participant was matched with a β-OHB measurement of 4.1 mmols/L.
Despite the advantages of the use of Point of Care meters for measuring capillary β-OHB, there
are limitations. According to Dhatariya [13], there is evidence of poor performance of Point of Care
meters at high levels of ketone concentration. This position is supported by Yu et al. [29] who
demonstrated that the use of Abbott meter for the measurement of β-OHB correlates well with the
reference laboratory method (Stanbio Assay) up to 3 mmol/L, and becomes discrepant after that value.
The authors further observed that while the Abbott meter may be useful for the diagnosis of DKA,
it may present challenges to clinicians in the management of patients with DKA who have β-OHB
values greater than 5 mmol/L (reference method) in hospital settings.
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8. Limitations of the Review
The different methods and designs of the studies included in this review made comparison of the
studies difficult. In addition, these studies were conducted in various countries around the world with
different research standards and quality.
9. Conclusions
The use of capillary β-OHB testing is more accurate than urinary ketone testing and compares
well with the enzymatic method. This approach will be useful in early identification of DKA.
Capillary β-OHB testing is a simple tool that is an accurate, precise method of early identification
of DKA in the Emergency Department and reduces unnecessary delays in diagnosis of DKA. Capillary
β-OHB and urine ketones had high sensitivity, but urine ketones had low specificity in identifying
DKA in the ED, with an error of almost 30% of false positive results. Capillary β-OHB testing is more
accurate than urine ketones, as accurate as manual enzymatic method, and highly correlated with
a clinical diagnosis of DKA.
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